Source author record

Yili Shen

Yili Shen appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
4topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2026arXiv

AgentTrap: Measuring Runtime Trust Failures in Third-Party Agent Skills

Third-party skills are becoming the package ecosystem for LLM agents. They package natural-language instructions, helper scripts, templates, documents, and service configuration into reusable workflows. This makes skills useful, but it also introduces a new security problem: a malicious skill does not need to ask the model to perform an obviously harmful action. Instead, it can disguise the harmful behavior as part of a routine workflow, relying on the agent to execute that workflow with high-value permissions and limited human supervision. We introduce AgentTrap, a dynamic benchmark for evaluating whether LLM agents can use third-party skills while resisting malicious runtime behavior. AgentTrap contains 141 tasks: 91 malicious tasks and 50 benign utility tasks, covering 16 security-impact dimensions grounded in agent-skill supply-chain threats. In each task, the agent receives an ordinary user request, runs with installed skills that may contain malicious workflow elements, and is executed in a sandboxed environment. AgentTrap then judges complete trajectories for attack success, blocked or refused behavior, attack-not-triggered cases, and no-attack-evidence outcomes. Our central finding is that the most informative failures are not simple jailbreaks. Models often complete the visible user task while treating unsafe side effects introduced by the skill as part of the normal workflow. This motivates runtime evaluation of the concrete model--framework--workspace environment in which users actually delegate work. Code and data are available at https://github.com/zhmzm/AgentTrap and https://huggingface.co/datasets/zhmzm/AgentTrap.

preprint2022arXiv

TCR: A Transformer Based Deep Network for Predicting Cancer Drugs Response

Predicting clinical outcomes to anti-cancer drugs on a personalized basis is challenging in cancer treatment due to the heterogeneity of tumors. Traditional computational efforts have been made to model the effect of drug response on individual samples depicted by their molecular profile, yet overfitting occurs because of the high dimension for omics data, hindering models from clinical application. Recent research shows that deep learning is a promising approach to build drug response models by learning alignment patterns between drugs and samples. However, existing studies employed the simple feature fusion strategy and only considered the drug features as a whole representation while ignoring the substructure information that may play a vital role when aligning drugs and genes. Hereby in this paper, we propose TCR (Transformer based network for Cancer drug Response) to predict anti-cancer drug response. By utilizing an attention mechanism, TCR is able to learn the interactions between drug atom/sub-structure and molecular signatures efficiently in our study. Furthermore, a dual loss function and cross sampling strategy were designed to improve the prediction power of TCR. We show that TCR outperformed all other methods under various data splitting strategies on all evaluation matrices (some with significant improvement). Extensive experiments demonstrate that TCR shows significantly improved generalization ability on independent in-vitro experiments and in-vivo real patient data. Our study highlights the prediction power of TCR and its potential value for cancer drug repurpose and precision oncology treatment.